Soleno Therapeutics, Inc. (SLNO) earnings
SLNO earnings moved a median of +0.44% by the close. Quarterly and annual SLNO reports and results, each read against the price at its own news timestamp. Back to the SLNO overview →
22 measured SLNO earnings events.
Where these SLNO earnings landedvs 22 measured SLNO earnings reactions
| Middle 50% of SLNO earnings reactions | -5.56% to +2.68% |
|---|---|
| Median reaction (to close) | +0.44% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 SLNO earnings events with a measured close landed between -5.56% and +2.68%; 55% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q SOLENO THERAPEUTICS INC For: Mar 31 | SEC filing · Form 10-Q | +0.01% | +0.00% | |
| Form 10-K/A SOLENO THERAPEUTICS INC For: Dec 31 | SEC filing · Form 10-K | +0.04% | +0.10% | |
| Form 10-K SOLENO THERAPEUTICS INC For: Dec 31 | SEC filing · Form 10-K | +1.11% | +5.40% | |
| Form 10-Q SOLENO THERAPEUTICS INC For: Sep 30 | SEC filing · Form 10-Q | -7.25% | -6.11% | |
| Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR | Press release | -7.25% | -6.11% | |
| Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET | Press release | +0.01% | +2.58% | |
| Form 10-Q SOLENO THERAPEUTICS INC For: Jun 30 | SEC filing · Form 10-Q | -1.05% | -5.65% | |
| Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results | Press release | -1.05% | -5.65% | |
| Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET | Press release | +0.10% | -1.57% | |
| Form 10-Q SOLENO THERAPEUTICS INC For: Mar 31 | SEC filing · Form 10-Q | -0.23% | +0.79% | |
| Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results | Press release | -0.23% | +0.79% | |
| Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET | Press release | -0.19% | -0.80% | |
| Form 10-K SOLENO THERAPEUTICS INC For: Dec 31 | SEC filing · Form 10-K | -1.08% | +9.19% | |
| Form 10-Q SOLENO THERAPEUTICS INC For: Sep 30 | SEC filing · Form 10-Q | +2.29% | +2.68% | |
| Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results | Press release | +2.29% | +2.68% | |
| Form 10-Q SOLENO THERAPEUTICS INC For: Jun 30 | SEC filing · Form 10-Q | -0.41% | +5.18% | |
| Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results | Press release | -0.41% | +5.18% | |
| Form 10-Q SOLENO THERAPEUTICS INC For: Mar 31 | SEC filing · Form 10-Q | -0.48% | -5.56% | |
| Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results | Press release | -0.48% | -5.56% | |
| Form 10-K SOLENO THERAPEUTICS INC For: Dec 31 | SEC filing · Form 10-K | -10.92% | +4.52% | |
| Form 10-Q SOLENO THERAPEUTICS INC For: Sep 30 | SEC filing · Form 10-Q | -3.17% | -6.64% | |
| Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results | Press release | -0.61% | +2.00% |
Keep exploring
More SLNO: analyst actions → · SEC filings → · SLNO overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CVS Health Corporation (CVS) | 1,095 | +0.02% | 51% |
| Idera Pharmaceuticals, Inc. (IDRA) | 1,094 | -0.27% | 42% |
| Zogenix, Inc. (ZGNX) | 1,086 | -0.08% | 45% |
| Reata Pharmaceuticals, Inc. - Class A (RETA) | 1,073 | +0.07% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.